K. Hoots

发表

HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage.

J. Goedert, M. Carrington, S. O’Brien, 1999, Science.

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

J. Rasko, M. Kay, J. Zehnder, 2006, Nature Medicine.

Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS.

J J Goedert, J. Goedert, M. Carrington, 2001, The New England journal of medicine.

Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study.

J J Goedert, J. Goedert, M. Carrington, 1997, Science.

The incidence and significance of hemostatic abnormalities in patients with head injuries.

P. Gildenberg, H. Kaufman, K. Wagner, 1989 .

Use of recombinant FVIIa for intraperitoneal coagulopathic bleeding in a septic patient.

J. Holcomb, K. Hoots, H. Neville, 2003, Current surgery.

Erratum: CORRIGENDUM: Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

M. Kay, M. Ozelo, J. F. Wright, 2006 .

Clotting factor concentrates and immune function in haemophilic patients

K. Hoots, D. Canty, 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

Treatment of an acquired coagulopathy with recombinant activated factor VII in a damage-control patient.

J. Holcomb, F. Moore, K. Hoots, 2005, Military medicine.

Association of DC-SIGN Promoter Polymorphism with Increased Risk for Parenteral, but Not Mucosal, Acquisition of Human Immunodeficiency Virus Type 1 Infection

J. Goedert, M. Carrington, M. Lederman, 2004, Journal of Virology.

variation differentially regulates influencing HIV disease outcome.

Takiguchi, J. Goedert, J. Margolick, 2019 .

A commentary on variant Creutzfeld‐Jacob disease

K. Hoots, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group.

H. Brackmann, I. Scharrer, T. Abshire, 2000, Thrombosis and haemostasis.

A mutation in KIR3DS1 that results in truncation and lack of cell surface expression

M. Carrington, J. Phair, S. O’Brien, 2007, Immunogenetics.

The effect of recombinant factor VIIa on noncoagulopathic pigs with grade V liver injuries.

D. Tweardy, J. Holcomb, M. Schreiber, 2003, Journal of the American College of Surgeons.

The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries.

J. Holcomb, M. Schreiber, S. Brundage, 2002, The Journal of trauma.

The incidence and significance of hemostatic abnormalities in patients with head injuries.

P. Gildenberg, T. W. O’Gorman, H. Kaufman, 1989, Neurosurgery.

Human immunodeficiency and hepatitis virus infections and their associated conditions and treatments among people with haemophilia

J. Goedert, J. Goedert, D. Brown, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention’s (CDC) Universal Data Collection (UDC) project

J. Gill, B. Evatt, J. Soucie, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors.

Roshni Kulkarni, Keith Hoots, Heather Huszti, 2004, Blood.

Therapeutic choices for patients with hemophilia and high‐titer inhibitors

M. Poon, L. Aledort, E. Berntorp, 2001, American journal of hematology.

The next generation of hemophilia treatment specialists.

E. Gomperts, E. Berntorp, K. Hoots, 2006, Seminars in thrombosis and hemostasis.

Sucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy

H. Brackmann, I. Scharrer, T. Abshire, 2000, Thrombosis and Haemostasis.

A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate®P/ Humate®‐P: History and clinical performance

P. Mannucci, G. Auerswald, M. Franchini, 2008, European journal of haematology. Supplementum.

Haemophilia prophylaxis: how can we justify the costs?

A. Willan, M. Carcao, W. Schramm, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group

L. Mantovani, A. Willan, M. Carcao, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

More on: are randomized clinical trials the only truth? Not always

P. Mannucci, C. Kessler, P. Monahan, 2006, Journal of thrombosis and haemostasis : JTH.

The optimal mode of delivery for the haemophilia carrier expecting an affected infant is caesarean delivery

A. James, K. Hoots, A. James, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Summary report of the First International Conference on inhibitors in haemophilia A.

L. Mantovani, P. Mannucci, F. Rosendaal, 2017, Blood transfusion = Trasfusione del sangue.

1002. Immune Responses to AAV and to Factor IX in a Phase I Study of AAV-Mediated, Liver-Directed Gene Transfer for Hemophilia B

J. Rasko, M. Kay, M. Ozelo, 2004 .

Economic aspects of haemophilia care

A. Miners, J. Goudemand, J. Wasserman, 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

Hepatitis C in adults and adolescents with hemophilia: A randomized, controlled trial of interferon alfa‐2b and ribavirin

N. Key, G. White, T. Abshire, 2002, Hepatology.

Medical countermeasures for radiation induced health effects: report of an Interagency Panel Session held at the NASA Human Research Program Investigator’s Workshop, 26 January 2017

Lisa S Carnell, Mary Homer, Keith Hoots, 2019, International journal of radiation biology.

Hypothermia and hemostasis in severe trauma: A new crossroads workshop report

K. Mann, P. Kochanek, P. Rhee, 2012, The journal of trauma and acute care surgery.

Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS

Keith Hoots, James J. Goedert, John Trowsdale, 2002, Nature Genetics.

Consistent Effects of TSG 101 Genetic Variability on Multiple Outcomes of Exposure to Human Immunodeficiency Virus Type 1 †

J. Goedert, M. Carrington, S. O’Brien, 2018 .

Consistent Effects of TSG101 Genetic Variability on Multiple Outcomes of Exposure to Human Immunodeficiency Virus Type 1

J. Goedert, M. Carrington, S. O’Brien, 2006, Journal of Virology.

AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis

J. Goedert, M. Altfeld, M. Carrington, 2005, Nature Medicine.

Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation

F B Taylor, F. Taylor, M. Levi, 2001, Thrombosis and Haemostasis.

Effects of plasma HIV RNA, CD4+ T lymphocytes, and the chemokine receptors CCR5 and CCR2b on HIV disease progression in hemophiliacs. Hemophilia Growth and Development Study.

S. O’Brien, C. Winkler, E. Daar, 1999, Journal of acquired immune deficiency syndromes.

Erratum: CORRIGENDUM: Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

M. Kay, M. Ozelo, J. F. Wright, 2006 .

ERRATUM: People to watch

J. Rasko, M. Kay, J. Zehnder, 2006, Nature Medicine.

from Hepatitis B 32 Favors Recovery Δ Variant and CCR5 Interaction between RANTES Promoter

J. Goedert, C. Thio, M. Witt, 2013 .

Interaction between RANTES Promoter Variant and CCR5Δ32 Favors Recovery from Hepatitis B1

J. Goedert, M. Carrington, C. Thio, 2008, Journal of Immunology.

Erratum: Therapeutic choices for patients with hemophilia and high-titer inhibitors (American Journal of Hematology (2001) 67 (240-246))

M. Poon, L. Aledort, E. Berntorp, 2002 .

Pediatric AIDS: Clinical, Pathologic, and Basic Science Perspectives. Conference proceedings. Washington, D.C., November 18-21, 1992.

Boechat, R. Elashoff, R. Mellins, 1993, Annals of the New York Academy of Sciences.

NHLBI strategic visioning: setting an agenda together for the NHLBI of 2025.

G. Mensah, J. Kiley, G. Gibbons, 2015, American journal of respiratory and critical care medicine.

Multilineage Immune-Mediated Cytopenias in Childhood: A Report of Five Patients.

C. Canpolat, K. Hoots, S. Culbert, 2000, Turkish journal of haematology : official journal of Turkish Society of Haematology.

Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery

L. Valentino, P. Mathew, S. Seremetis, 2007, Thrombosis and Haemostasis.

The pediatric pulmonary and cardiovascular complications of vertically transmitted human immunodeficiency virus (P2C2 HIV) infection study: design and methods. The P2C2 HIV Study Group.

Robert H. Cleveland, M. Schluchter, G. Beck, 1996, Journal of clinical epidemiology.

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry

P. Marks, A. Angiolillo, L. Valentino, 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

Hepatitis C in adults and adolescents with hemophilia: A randomized, controlled trial of interferon alfa‐2b and ribavirin

N. Key, G. White, T. Abshire, 2002, Hepatology.

Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team.

M. Lederman, C. Yiannoutsos, K. Marder, 1999, AIDS.

‘What wound did ever heal but by degrees?’ *

K. Hoots, 2007, Journal of thrombosis and haemostasis : JTH.

Acquired immunodeficiency syndrome-associated non-Hodgkin's lymphomas and other malignancies in patients with hemophilia.

L. Kingsley, S. Belle, D. Brettler, 1993, Blood.

On the value of portfolio diversity in heart, lung, and blood research.

M. Lauer, J. Kiley, Z. Galis, 2012, American journal of respiratory and critical care medicine.

Prevalence of conditions associated with human immunodeficiency and hepatitis virus infections among persons with haemophilia, 2001–2003

J. Goedert, M. Lederman, J. Goedert, 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

A multicenter study of viral hepatitis in a United States hemophilic population.

R. Parmley, C. Contant, J. Gill, 1993, Blood.